CA3244131A1 - CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE - Google Patents
CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVEInfo
- Publication number
- CA3244131A1 CA3244131A1 CA3244131A CA3244131A CA3244131A1 CA 3244131 A1 CA3244131 A1 CA 3244131A1 CA 3244131 A CA3244131 A CA 3244131A CA 3244131 A CA3244131 A CA 3244131A CA 3244131 A1 CA3244131 A1 CA 3244131A1
- Authority
- CA
- Canada
- Prior art keywords
- administration period
- subject
- months
- prior
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263310751P | 2022-02-16 | 2022-02-16 | |
| US63/310,751 | 2022-02-16 | ||
| PCT/US2023/062731 WO2023159120A1 (en) | 2022-02-16 | 2023-02-16 | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3244131A1 true CA3244131A1 (en) | 2023-08-24 |
Family
ID=87579133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3244131A Pending CA3244131A1 (en) | 2022-02-16 | 2023-02-16 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250144116A1 (https=) |
| EP (1) | EP4479059A4 (https=) |
| JP (1) | JP2025508359A (https=) |
| KR (1) | KR20240148350A (https=) |
| CN (1) | CN118695864A (https=) |
| AU (1) | AU2023221393A1 (https=) |
| CA (1) | CA3244131A1 (https=) |
| GB (1) | GB2630719A (https=) |
| IL (1) | IL314769A (https=) |
| MX (1) | MX2024009995A (https=) |
| WO (1) | WO2023159120A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (https=) | 2014-01-24 | 2018-02-24 | ||
| HUE070049T2 (hu) | 2018-03-01 | 2025-05-28 | Astrazeneca Ab | (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények |
| WO2020018547A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (https=) * | 2014-01-24 | 2018-02-24 | ||
| KR20240091302A (ko) * | 2016-07-29 | 2024-06-21 | 인스메드 인코포레이티드 | 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드 |
| CA3089240A1 (en) * | 2018-02-07 | 2019-08-15 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides |
| MX2021012548A (es) * | 2019-04-17 | 2023-01-05 | Azora Therapeutics Inc | Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel. |
| WO2024026433A2 (en) * | 2022-07-28 | 2024-02-01 | Insmed Incorporated | Novel dpp1 inhibitors and uses thereof |
-
2023
- 2023-02-16 EP EP23757082.5A patent/EP4479059A4/en active Pending
- 2023-02-16 CN CN202380021843.7A patent/CN118695864A/zh active Pending
- 2023-02-16 GB GB2412566.8A patent/GB2630719A/en active Pending
- 2023-02-16 WO PCT/US2023/062731 patent/WO2023159120A1/en not_active Ceased
- 2023-02-16 IL IL314769A patent/IL314769A/en unknown
- 2023-02-16 US US18/838,823 patent/US20250144116A1/en active Pending
- 2023-02-16 MX MX2024009995A patent/MX2024009995A/es unknown
- 2023-02-16 KR KR1020247027154A patent/KR20240148350A/ko active Pending
- 2023-02-16 JP JP2024546431A patent/JP2025508359A/ja active Pending
- 2023-02-16 CA CA3244131A patent/CA3244131A1/en active Pending
- 2023-02-16 AU AU2023221393A patent/AU2023221393A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250144116A1 (en) | 2025-05-08 |
| CN118695864A (zh) | 2024-09-24 |
| WO2023159120A1 (en) | 2023-08-24 |
| IL314769A (en) | 2024-10-01 |
| KR20240148350A (ko) | 2024-10-11 |
| MX2024009995A (es) | 2024-08-22 |
| EP4479059A4 (en) | 2026-01-28 |
| AU2023221393A1 (en) | 2024-08-15 |
| EP4479059A1 (en) | 2024-12-25 |
| JP2025508359A (ja) | 2025-03-26 |
| GB2630719A (en) | 2024-12-04 |
| GB202412566D0 (en) | 2024-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250144116A1 (en) | Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa | |
| US20220152052A1 (en) | Methods and compositions for treating various disorders | |
| JP2022001592A (ja) | 代謝障害を治療するための組成物および方法 | |
| Camras et al. | Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery | |
| US20250049813A1 (en) | Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis | |
| JP2018087214A (ja) | スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物 | |
| US20230338367A1 (en) | Treatment of prurigo nodularis | |
| CN118105392A (zh) | 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型 | |
| JP2024133735A (ja) | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 | |
| KR20240004691A (ko) | 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드 | |
| JP2013199506A (ja) | 処置方法 | |
| CA2555316A1 (en) | Combined pharmaceutical composition | |
| WO2020014342A1 (en) | Treatment of the pruritic symptoms of liver disease | |
| TW200529847A (en) | Pharmaceutical composition for use in the treatment of chronic fatigue syndrome or fibromyalgia or associated functional symptoms of fibromyalgia | |
| BRPI0713647A2 (pt) | formulações farmacêuticas e composições de um antagonista seletivo cxcr2 ou cxcr1 e métodos para o uso do mesmo visando o tratamento de distúrbios inflamatórios | |
| US20260108483A1 (en) | Methods and compositions for preventing the progression of diabetic retinopathy and related conditions | |
| KR20260021653A (ko) | IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄 | |
| AU2024278948A1 (en) | Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness | |
| WO2024231312A2 (en) | Combination therapy | |
| HK40003409A (en) | Treatment of prurigo nodularis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240813 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240816 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240816 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240816 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241107 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20241107 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241113 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250130 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250130 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250130 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250211 |